Corcept Therapeutics | CORT - Net Income


Corcept Therapeutics reported $24.29M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Alaunos Therapeutics USD -1.16M 417K Sep/2025
ANI Pharmaceuticals USD 26.27M 18.13M Sep/2025
Ardelyx USD -969K 18.11M Sep/2025
Assertio Holdings USD -2.92M 753K Sep/2024
Aurora Cannabis CAD -51.47M 36.26M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Canopy Growth CAD -1.64M 39.89M Sep/2025
Corcept Therapeutics USD 24.29M 4.62M Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
J&J USD 5.12B 36M Dec/2025
Knight Therapeutics CAD 85K 2.03M Sep/2024
Lexicon Pharmaceuticals USD -53.43M 5.03M Jun/2024
Merck USD 2.96B 2.82B Dec/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Novartis USD 3.93B 96M Sep/2025
Novartis USD 3.93B 113M Sep/2025
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 5.43M 10.28M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Supernus Pharmaceuticals USD -45.12M 67.62M Sep/2025
TG Therapeutics USD 390.9M 362.71M Sep/2025